AIM2 and fatty liver disease: Overexpression of farnesoid X receptor (FXR), (NSAID)‐activated gene‐1 (NAG‐1), and growth differentiation factor‐15 (GDF15) ameliorates liver steatosis, reduces lipogenesis, and enhances lipolysis and fatty acid β‐oxidation, while concurrently suppressing AIM2 inflammasome activation.23, 126